Free tool
FAERS Monitor: Enzeevu
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761382 or its brand name (Enzeevu, Aflibercept-Abzv). Reports on generic versions are filed under their own applications.
Reports
3,454
Serious
3,281
95% of reports
Hospitalization
1,431
Death reported
418
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use450
- diarrhoea377
- neutropenia215
- hypertension204
- asthenia152
- disease progression147
- visual acuity reduced141
- drug ineffective122
- fatigue118
- endophthalmitis116
- nausea116
- thrombocytopenia106
- general physical health deterioration100
- abdominal pain99
- anaemia99
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 5 |
| 2008 | 2 |
| 2009 | 11 |
| 2010 | 45 |
| 2011 | 27 |
| 2012 | 57 |
| 2013 | 240 |
| 2014 | 162 |
| 2015 | 159 |
| 2016 | 180 |
| 2017 | 182 |
| 2018 | 532 |
| 2019 | 328 |
| 2020 | 212 |
| 2021 | 200 |
| 2022 | 170 |
| 2023 | 198 |
| 2024 | 203 |
| 2025 | 238 |
| 2026 | 303 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,705 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| endophthalmitisSignal | 116 | 120.0 | 100.2 | 13,317 |
| visual acuity reducedSignal | 141 | 26.0 | 22.1 | 3,350 |
| neutropeniaSignal | 215 | 9.6 | 8.5 | 1,665 |
| disease progressionSignal | 147 | 7.6 | 6.5 | 836 |
| hypertensionSignal | 204 | 5.9 | 5.1 | 827 |
| thrombocytopeniaSignal | 106 | 5.8 | 4.8 | 416 |
| general physical health deteriorationSignal | 100 | 5.3 | 4.3 | 343 |
| diarrhoeaSignal | 377 | 3.6 | 3.2 | 712 |
| anaemiaSignal | 99 | 3.2 | 2.6 | 145 |
| off label useSignal | 450 | 3.1 | 2.9 | 678 |
| abdominal painSignal | 99 | 2.6 | 2.1 | 96 |
| astheniaSignal | 152 | 2.5 | 2.1 | 133 |
| fatigue | 118 | 0.9 | 0.8 | 1 |
| nausea | 116 | 0.9 | 0.7 | 1 |
| drug ineffective | 122 | 0.6 | 0.5 | 43 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.